Clinical Trial Results: Positive outcomes in clinical trials for Simufilam, Cassava Sciences' Alzheimer's drug, typically lead to significant stock price increases. Conversely, negative or inconclusive results can cause sharp declines. Regulatory Decisions: Decisions made by the FDA, such as approval, rejection, or requests for additional data regarding Simufilam, have a direct and substantial impact on SAVA's stock price. Financial Performance: Cassava Sciences' financial health, including cash reserves, spending rate, and ability to secure funding, plays a role. Concerns about financial stability can negatively affect investor confidence. Market Sentiment: Overall investor sentiment towards biotechnology companies, particularly those focused on Alzheimer's disease, influences SAVA's stock. General market optimism tends to lift SAVA, while pessimism can drag it down. Competition: Progress made by competitors in developing Alzheimer's treatments affects SAVA. The emergence of more effective or safer alternatives could diminish the potential market for Simufilam. Scientific Publications: Peer-reviewed publications supporting the efficacy and safety of Simufilam can boost investor confidence, while criticisms or challenges to the underlying science can have the opposite effect. Short Interest: The level of short interest in SAVA shares can influence price volatility. High short interest can lead to short squeezes if positive news emerges, driving the price up sharply. News and Rumors: News articles, social media discussions, and rumors regarding Cassava Sciences, its executives, or Simufilam can create volatility in the stock price, even if the information is unconfirmed.